csirt@kutim:~/threat-intel/cve/CVE-2026-103923

Katalog CVE

CVSS 2.1 · Low EPSS 0,30%

Kerentanan Reliance on Untrusted Inputs in a Security Decision. Skor CVSS 4.0 2.1 (Low) menurut github.com.

Deskripsi (NVD)

KaTeX is a fast, easy-to-use JavaScript library for TeX math rendering on the web. From 0.11.0 until 0.18.2, KaTeX uses ordinary JavaScript property access for the renderer options object, the trust setting, default and processor setting metadata, and namespace lookup and group restoration, allowing inherited properties to be treated as explicitly supplied values. When Object.prototype is already polluted or an attacker controls the options object's prototype, attacker-controlled mathematical expressions can use an inherited trust value to enable trusted rendering and produce links capable of user-interaction cross-site scripting or loading attacker-selected external resources in a consuming application that inserts unsanitized KaTeX output into a page. KaTeX does not itself create the prototype pollution, and rendering an expression alone does not execute script. This issue is fixed in version 0.18.2.

Rincian

Terbit di NVD
1 Oktober 2026
Terakhir diubah
6 Oktober 2026
Status NVD
Awaiting Analysis
CVSS 4.0
2.1 (Low), sumber github.com
CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:A/VC:N/VI:N/VA:N/SC:L/SI:L/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X · uraikan di kalkulator
Jenis kelemahan (CWE)
CWE-807: Reliance on Untrusted Inputs in a Security Decision
EPSS (30 hari)
0,30% peluang dieksploitasi; lebih tinggi dari 21,4% CVE lain

Produk dan versi terdampak

NVD belum mencantumkan data produk (CPE) untuk CVE ini. Produk yang terdampak biasanya disebut di deskripsi dan di advisory vendor pada daftar referensi.

Referensi dan perbaikan

Sumber: NVD · CVE.org · EPSS. Halaman ini disusun otomatis dari data tersebut; pembaruan terakhir 6 Okt 2026, 12:25 WITA. Kalau sistem di Perangkat Daerah memakai produk ini dan butuh bantuan, laporkan lewat kanal pelaporan.